ViferaXS GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ViferaXS GmbH - overview
Established
2022
Location
Tubingen, -, Germany
Primary Industry
Biotechnology
About
Founded in 2022 and based in Tubingen, Germany, ViferaXS GmbH operates as a biotechnology company developing peptide-based cancer treatments that stimulate T-cell immune responses.
Current Investors
Huma Therapeutics GmbH, SPRIND
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.viferaxs.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
ViferaXS GmbH - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant | Completed | ViferaXS GmbH | - | ||||||||
| Series A | Completed | ViferaXS GmbH | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.